Key points are not available for this paper at this time.
BACKGROUND: Enhanced nocturnal heart rate variability (HRV) has been evoked in sleep-related breathing disorders. However, its capacity to detect obstructive sleep apnea syndrome (OSAS) has not been systematically determined. Thus, we evaluated the discriminant power of HRV parameters in a first group of patients (G1) and validated their discriminant capacity in a second group (G2). METHODS AND RESULTS: In G1, 39 of 91 patients (42.8%) were identified as diseased by polysomnography, as were 24 of 52 patients (46%) in G2. Time-domain HRV variables (SD of NN intervals SDNN, mean of the standard deviations of all NN intervals for all consecutive 5-minute segments of the recording SDNN index, square root of the mean of the sum of the squares of differences between adjacent normal RR intervals r-MSSD, and SD of the averages of NN intervals in all 5-minute segments of the recording SDANN) were calculated for daytime and nighttime periods, as well as the differences between daytime and nighttime values (DeltaD/N). Correlations between HRV variables and OSAS status were analyzed in G1 by use of receiver-operating characteristic (ROC) curves and logistic regression analysis. By ROC curve analysis, 7 variables were significantly associated with OSAS. After adjustment for other variables through multiple logistic regression analysis, DeltaD/NSDNN index and DeltaD/N r-MSSD remained significant independent predictors of OSAS, with ORs of 8.22 (95% CI, 3.16 to 21.4) and 2.86 (95% CI, 1.21 to 6.75), respectively. The classification and regression tree methodology demonstrated a sensitivity reaching 89.7% (95% CI, 73.7 to 97.7) with DeltaD/N SDNN index and a specificity of 98.1% (95% CI, 86.4 to 100) with DeltaD/N SDNN using appropriate thresholds. These thresholds, applied to G2, yielded a sensitivity of 83% using DeltaD/N SDNN index and a specificity of 96.5% using DeltaD/N SDNN. CONCLUSIONS: Time-domain HRV analysis may represent an accurate and inexpensive screening tool in clinically suspected OSAS patients and may help focus resources on those at the highest risk.
Roche et al. (Tue,) studied this question.